NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT01327612 2021-02-21Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)AmgenPhase 2 Completed12 enrolled 21 charts